Hims & Hers Health (HIMS) Expected to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is expected to release its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.0490) per share and revenue of $698.90 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Up 0.1%

HIMS opened at $27.79 on Monday. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The stock’s fifty day simple moving average is $31.23 and its 200 day simple moving average is $26.08. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The stock has a market cap of $6.43 billion, a PE ratio of -308.74, a price-to-earnings-growth ratio of 78.15 and a beta of 2.35.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Bank of America upped their price target on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Finally, Barclays raised their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $31.43.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Irene Becklund sold 7,573 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the completion of the transaction, the insider owned 11,280 shares in the company, valued at $341,220. This trade represents a 40.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. State Street Corp grew its position in shares of Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Invesco Ltd. raised its position in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares in the last quarter. Marex Group plc raised its position in shares of Hims & Hers Health by 162.2% in the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after buying an additional 1,496,707 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Hims & Hers Health by 1.4% in the third quarter. Northern Trust Corp now owns 2,415,158 shares of the company’s stock valued at $136,988,000 after buying an additional 32,236 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Hims & Hers Health by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,398,008 shares of the company’s stock valued at $77,863,000 after buying an additional 42,569 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.